Stock Analysis, Dividends, Split History

RTIX / RTI Surgical, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)288.37
Enterprise Value ($M)327.54
Book Value ($M)176.07
Book Value / Share2.78
Price / Book1.64
NCAV ($M)63.42
NCAV / Share1.00
Price / NCAV4.55
Share Statistics
Temporary Equity Shares Outstanding 50,000
Common Shares Outstanding 62,757,731
Common Stock Shares Outstanding 58,433,397
Scoring Models
Piotroski F-Score7.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.03
Return on Assets (ROA)0.02
Return on Equity (ROE)0.04
Balance Sheet (mrq) ($M)
Quick Ratio1.55
Current Ratio3.86
Income Statement (mra) ($M)
Sales Revenue Services Net0.00
Number Of Independent Companies With Significant Revenues2.00
Other Sales Revenue Net10,423,000.00
Sales Revenue Net279,563,000.00
Operating Income28.81
Net Income6.27
Earnings Per Share Diluted0.04
Earnings Per Share Basic0.04
Cash Flow Statement (mra) ($M)
Cash From Operations2.46
Cash from Investing38.25
Cash from Financing2.46
Identifiers and Descriptors
Central Index Key (CIK)1100441
Related CUSIPS

Split History

Stock splits are used by RTI Surgical, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

Is RTI Surgical (RTIX) Stock Undervalued Right Now?

2018-08-14 zacks
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers. (2-0)

Xtant Medical Holdings, Inc. (XTNT) CEO Carl O'Connell on Q2 2018 Results - Earnings Call Transcript

2018-08-11 seekingalpha
Xtant Medical Holdings, Inc. (NYSEMKT:XTNT) Q2 2018 Results Earnings Conference Call August 8, 2018 9:00 AM ET (26-0)

RTIX or INGN: Which Is the Better Value Stock Right Now?

2018-08-07 zacks
Investors interested in Medical - Instruments stocks are likely familiar with RTI Surgical (RTIX - Free Report) and Inogen (INGN - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. (2-0)

Your Daily Pharma Scoop: Epizyme Down, MiMedx Proceeds, Summit Beats

2018-08-05 seekingalpha
Epizyme down 8% premarket on termination of tazemetostat in DLBCL & delay in NDA filing for ES (42-2)

RTI Surgical's (RTIX) CEO Camille Farhat on Q2 2018 Results - Earnings Call Transcript

2018-08-04 seekingalpha
Good day, ladies and gentlemen, and welcome to the RTI Surgical Second Quarter Earning Conference. At this time all participants are in a listen-only mode. [Operator Instructions] As a reminder, this call is being recorded. (2-0)

Silicon Investor Message Boards

This table lists all message boards related to RTIX / RTI Surgical, Inc. on message board site Silicon Investor.

RTIX: Regeneration Technologies RTIX: Regeneration Technologies RTIX: Regeneration Technologies Regeneration Technologies (RTIX) Regeneration Technologies (RTIX) Regeneration Technologies (RTIX)
CUSIP: 74975N105